Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.

@article{Cheng2006ParicalcitolCF,
  title={Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.},
  author={Steven C Cheng and Daniel W. Coyne},
  journal={Expert opinion on pharmacotherapy},
  year={2006},
  volume={7 5},
  pages={617-21}
}
Secondary hyperparathyroidism is a common complication of patients with chronic kidney disease. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in elevations in serum calcium and phosphorus. New vitamin D analogues have been developed to reduce parathyroid hormone secretion without concomitant hypercalcaemia and hyperphosphataemia. Recent data from studies with paricalcitol capsules, the oral formulation of 19-nor-1,25(OH)2D2, show a… CONTINUE READING